Dr. Gordon’s Comments:

I do not use aspirin for primary prevention for any of my patients. The benefits are too small and the risks are real. It has clearly been oversold and misrepresented. It never has been an anticoagulant, but it does have some limited antiplatelet effects. On the whole it has some benefits but there are also some bleeding risks.

Moreover, since it does not decrease deaths from heart attacks or all-cause mortality, the patients are living with false sense of security and will ignore advice to be on a product that could clearly add years to their life but does not have all the marketing money behind it. Beyond Chelation-Improved is the real protection patients are seeking.

Patients who I clearly can help decrease all cause morbidity and mortality without question using Beyond Chelation Improved and, particularly for serious cases, adding Boluoke BID to the program, are not getting the message, as they believe in the hype surrounding aspirin. I can state unequivocally BC-I and Boluoke together do dramatically lower mortality from heart attacks even in patients with high risk documented left main disease. It also lowers all-cause mortality while also lowering stroke incidences.

The reasons are clear if you consider that BC-I has over 100 active ingredients and over $10 million in research behind it. BC-I has three books written about how it was developed and it took over $10 million back in the sixties to develop this natural approach to ending heart attacks and that was real money back then. There are two published studies where it lowered heart attacks by an average of 91% but that was some time before I added the EDTA to the formula. I believe that the benefits are even greater now.

So let’s take the time to learn the truth about the limitations of aspirin. For as long as your patients believe that their aspirin has made them less subject to death, they will have little real interest in learning about a product that really works, but takes real money to purchase every day of their life.

Attached is the conclusion of this large meta analysis report linked here: “There was no evidence of a statistical bias (p >0.05). In conclusion, aspirin decreased the risk for CV events and nonfatal MI in this large sample. Thus, primary prevention with aspirin decreased the risk for total CV events and nonfatal MI, but there were no significant differences in the incidences of stroke, CV mortality, all-cause mortality and total coronary heart disease.”

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Link: http://www.ajconline.org/article/S0002-9149(11)01013-7/fulltext

Excerpt:

Systematic analysis of the outcomes from the 9 trials confirmed that aspirin decreases the incidence of nonfatal MI and CV events. However, aspirin had no statistically significant effect on CHD, stroke, CV mortality, and all-cause mortality, but was highly significant for overall CV events.